Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419821 | 0.85 | LMNA (0.34) | CTSLCTSBCTSKDPP4MEN1 | |
| SCHEMBL420096 | 0.85 | OPRM1 (0.46) | CTSLCTSBCTSKDPP4NAAA | |
| SCHEMBL420505 | 0.79 | SPHK1 (0.39) | CNR2MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL418753 | 0.72 | CTSL (0.40) | CTSLCTSBCTSKDPP4NAAA | |
| SCHEMBL420095 | 0.72 | CTSL (0.40) | CTSLCTSBCTSKDPP4NAAA | |
| SCHEMBL4028340 | 0.72 | SLC6A2 (0.41) | CNR2MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL4027422 | 0.72 | SLC6A2 (0.41) | CNR2MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL4027425 | 0.72 | SLC6A2 (0.41) | CNR2MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL5522000 | 0.70 | LMNA (0.36) | CTSLCTSBCTSKCNR2MEN1 | |
| SCHEMBL5521995 | 0.70 | LMNA (0.36) | CTSLCTSBCTSKCNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | CTSL 2286/4885CTSB 3474/4885CTSK 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.